SOCS1 and viral infectious disease: Given that our SOCS1/3 antagonist is effective against a broad group of viruses, such as HSV-1, vaccinia virus, EMC virus, and here against influenza virus, we feel that it should be a candidate for treatment of virus infections in general, including that of the Ebola virus and members of the Flaviviridae family.